GlycoNex wins Japan nod to launch first human trial of lead program in gastrointestinal cancers

The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy

FDA grants priority review to Daiichi Sankyo & Merck’s lung cancer drug application

The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck

Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies

The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio

Vir Biotechnology advances VIR-5500 into expansion trials in prostate cancer

Imagene AI teams up with Daiichi Sankyo to supercharge cancer drug development

A major push to sharpen the future of cancer treatment is underway

Max Institute of Cancer Care, Vaishali showcases advanced oncology technologies at ONCO-CON 2026

The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care

New guidance aims to speed up diagnosis of childhood abdominal cancers

Backed by funding from an NIHR Doctoral Award, the guidance is focused on spotting abdominal tumours

Boehringer Ingelheim & BioNTech launch high-stakes lung cancer combo trial

BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study

FDA fast-tracks Daiichi Sankyo & Merck lung cancer drug review

The FDA is also reviewing the application under its Real-Time Oncology Review (RTOR) program and Project Orbis

Eli Lilly posts strong Phase 3 win for Jaypirca combo in blood cancer trial

Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors